Detailed Coverage

RPG Life Sciences Reports Strong Q1 FY27 Growth

Revenue in Q1 FY27 stood at ₹195.69 crore, while Net Profit was ₹30.57 crore.
Reader Takeaway: Revenue and profit growth driven by core pharma business; API division transfer progress is key.

What just happened

RPG Life Sciences announced its financial results for the first quarter of FY27 (ended June 30, 2026). The company reported standalone revenue from operations of ₹195.69 crore, a 16% increase from ₹168.92 crore in the same period last year.

Standalone net profit for the quarter rose by 16.4% to ₹30.57 crore, up from ₹26.29 crore in Q1 FY26. The basic Earnings Per Share (EPS) was reported at ₹18.49.

Why this matters

These results indicate a healthy growth trajectory for RPG Life Sciences, with both top-line and bottom-line figures showing significant year-over-year improvement. This suggests sustained demand and effective operations within its pharmaceutical segment.

The backstory

The company is currently in the process of transferring its Active Pharmaceutical Ingredient (API) division to a wholly-owned subsidiary, RPG Active Pharma Limited. This strategic move is subject to regulatory approvals and other standard conditions.

The financial results for Q1 FY27 are consolidated and include the performance of this subsidiary, reflecting the ongoing restructuring.

What changes now

Investors will be closely watching the progress and completion of the API division transfer. This move aims to streamline operations and potentially unlock value. The continued growth in the core business provides a stable base as this restructuring takes place.

Risks to watch

Any delays or challenges in obtaining the necessary consents for the API division transfer could impact the company's restructuring plans and future outlook.

Peer comparison

RPG Life Sciences operates within the pharmaceutical sector, a competitive industry in India. Companies like Divi's Laboratories, Laurus Labs, and Aarti Drugs are also key players in the API and formulation space.

Context metrics (time-bound)

• Revenue (Q1 FY27): ₹195.69 crore (vs. ₹168.92 crore in Q1 FY26)
• Net Profit (Q1 FY27): ₹30.57 crore (vs. ₹26.29 crore in Q1 FY26)
• EPS (Basic) (Q1 FY27): ₹18.49

What to track next

Investors should monitor updates on the completion of the API division transfer to RPG Active Pharma Limited, including any regulatory milestones. Continued financial performance demonstrating sustained growth in the pharmaceutical segment will also be crucial.